AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2016
May 4, 2016
30583_dirs_2016-05-04_32ecaccd-38ab-457c-975f-e45c2a8b58a0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2016-04-29
Reporting Person: Ajer Jeffrey Robert (EVP, Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-04-29 | Common Stock | A | 415 | $51.264 | Acquired | 63487 | Direct |
| 2016-05-03 | Common Stock | S | 415 | $86.0259 | Disposed | 63072 | Direct |
Footnotes
F1: The reporting person is reporting the purchase of shares of the issuer's Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 1, 2015 to April 30, 2016.
F2: Transaction made pursuant to a Rule 10b5-1 trading plan executed on May 11, 2015.
F3: The price in column 4 is a weighted average price. The price actually received ranged from $85.32 to $86.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range